COTA and GTC Partner to Improve Precision Oncology

COTA, an oncology real-world data and analytics company, has announced a new partnership with Genomic Testing Cooperative (GTC), a molecular testing company. The two companies are joining forces to integrate COTA’s deep clinical oncology real-world data with GTC’s comprehensive genomics testing data. This strategic and oncology-specific partnership, grounded in deep comprehensive clinical data, will support more precise, personalised cancer research particularly across early discovery and translational epidemiology functions.

Genomic Testing Cooperative’s innovative approach to genetic testing provides valuable molecular information, which is critical for determining the correct patient diagnosis and selecting the most appropriate treatment. GTC tissue-based and liquid biopsy testing uniquely leverages DNA and RNA sequencing for both solid and hematologic cancers to generate information on mutations, chromosomal structural abnormalities, biomarkers that can replace or complement immunohistochemistry, flow cytometry, and standard tumour markers. This comprehensive profiling is captured before treatment and frequently after relapse so a fuller picture of treatment impact on a specific patient population can be understood.

“Care teams and researchers simply can’t make the highest quality decisions for patients if they don’t have advanced oncology real-world data coupled with genomic testing data that fully reflects the patient journey,” said Miruna Sasu, President and CEO at COTA. “While COTA previously had access to clinically actionable biomarker data, it was not as complete as what GTC offers today. Our partnership will provide researchers and clinicians with the multi-modal data needed to conduct more targeted research and deliver personalised cancer treatments that result in the best possible outcomes for patients.”

This latest partnership builds on COTA’s recent announcement with the Clinical Research Data Sharing Alliance (CRDSA) and its broader focus on bringing clarity to cancer care. Earlier in February, COTA joined CRDSA, a collection of biopharma companies, data sharing platforms, academic institutions, and service and technology partners, focused on ushering in the next generation of data-driven healthcare.

Click here to read the original news story.

Looking for expert insights in Digital Health for Oncology? Join the HealthXL Meeting on ‘Patient Engagement Metrics in Digital Health for Oncology’ on 14th March. Click here to Request to Join.